羟基氯喹
氯喹
2019年冠状病毒病(COVID-19)
医学
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
药理学
冠状病毒
2019-20冠状病毒爆发
病毒学
药品
大流行
传统医学
疾病
爆发
疟疾
免疫学
传染病(医学专业)
内科学
作者
Li Zou,Lijun Dai,Xingyu Zhang,Zhaohui Zhang,Zhentao Zhang
标识
DOI:10.1007/s12272-020-01258-7
摘要
A novel coronavirus, later named SARS-CoV-2, was first reported in China in December 2019 and subsequently widely identified in the United States, Japan, South Korea, France, India, and other countries. The disease caused by SARS-CoV-2 infection was called COVID-19. The high fatality and morbidity rates of COVID-19 make it the third largest global epidemic in this century. However, there are currently no approved antiviral drugs for the COVID-19 treatment. Recently, two old antimalarial drugs, hydroxychloroquine and chloroquine, have been found to exert anti-SARS-CoV-2 effects both in vitro and in vivo. Preliminary clinical evidence suggests these drugs may have an effect on the treatment of COVID-19. Herein, we review the pharmacokinetics characteristics and antiviral effects of these drugs, in addition to their side effects and clinical evidence of their use for the COVID-19 treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI